Clinical Trial Update: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms [Phase 1]

View source ↗

Summary

Phase 1 study of brentuximab vedotin given sequentially and in combination with multi-agent chemotherapy for CD30-positive mature T-cell and NK-cell neoplasms h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Natural Killer Cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell | Phase 1 | Status: COMPLETED